User menu

Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent

Bibliographic reference Ni, YC ; Chen, F. ; Mulier, Stefaan ; Sun, XH ; Yu, J ; et. al. Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent. In: European Radiology : journal of the European Congress of Radiology, Vol. 16, no. 5, p. 1031-1040 (2006)
Permanent URL
  1. Ni Y, Mulier S, Miao Y, Michel L, Marchal G (2005) A review of the general aspects of radiofrequency ablation. Abdom Imaging 30:381–400
  2. Hynynen K, McDannold N (2004) MRI guided and monitored focused ultrasound thermal ablation methods: a review of progress. Int J Hyperthermia. 20:725–737
  3. Antoch G, Vogt FM, 4 P, Freudenberg LS, Blechschmid N, Dirsch O, Bockisch A, Forsting M, Debatin JF, Kuehl H (2005) Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med 46:520–525
  4. Dromain C, de Baere T, Elias D, Kuoch V, Ducreux M, Boige V, Petrow P, Roche A, Sigal R (2002) Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 223:255–262
  5. Tsuda M, Majima K, Yamada T, Saitou H, Ishibashi T, Takahashi S (2001) Hepatocellular carcinoma after radiofrequency ablation therapy: dynamic CT evaluation of treatment. Clin Imaging. 25:409–415
  6. Bartolozzi C, Crocetti L, Cioni D, Donati FM, Lencioni R (2001) Assessment of therapeutic effect of liver tumor ablation procedures. Hepatogastroenterology. 48:352–358
  7. Kim TJ, Moon WK, Cha JH, et al (2005) VX2 carcinoma in rabbits after radiofrequency ablation: Comparison of MR contrast agents for help in differentiating benign periablational enhancement from residual tumor. Radiology 234:423–430
  8. Goldberg SN (2005) Can we differentiate residual untreated tumor from tissue responses to heat following thermal tumor ablation? Radiology 234:317–318
  9. Ni Y, Chen F, Marchal G (2005) Differentiation of residual tumor from benign periablational tissues after radiofrequency ablation: the role of MRI contrast agents (letter). Radiology 237:745–749
  10. Ni Y, Bormans G, Chen F, Verbruggen A, Marchal G (2005) Necrosis avid contrast agents: functional similarity versus structural diversity (review). Invest Radiol 40:526–535
  11. Marchal G, Ni Y, Herijgers P, Flameng W, Petré C, Bosmans H, Yu J, Ebert W, Hilger CS, Pfefferer D, Semmler W, Baert AL (1996) Paramagnetic metalloporphyrins: infarct avid contrast agents for diagnosis of acute myocardial infarction by magnetic resonance imaging. Eur Radiol 6:1–8
  12. Ni Y, Marchal G, Herijgers P, et al (1996) Paramagnetic metalloporphyrins: from enhancers for malignant tumors to markers of myocardial infarcts. Acad Radiol 3:S395–S397
  13. Ni Y (1998) Myocardial viability. In: Bogaert J, Duerinckx AL, Rademakers FE (eds) Magnetic resonance of the heart and great vessels: clinical applications, 1st edn, Springer, Berlin Heidelberg New York, pp 113–132
  14. Pislaru S. V., Ni Y., Pislaru C., Bosmans H., Miao Y., Bogaert J., Dymarkowski S., Semmler W., Marchal G., Van de Werf F. J., Noninvasive Measurements of Infarct Size After Thrombolysis With a Necrosis-Avid MRI Contrast Agent, 10.1161/01.cir.99.5.690
  15. Choi Sang Il, Choi Seong Hoon, Kim Sang Tae, Lim Keun Ho, Lim Chung Hwan, Gong Gyung Yub, Kim Hyae Young, Weinmann Hanns-Joachim, Lim Tae-Hwan, Irreversibly Damaged Myocardium at MR Imaging with a Necrotic Tissue-Specific Contrast Agent in a Cat Model, 10.1148/radiology.215.3.r00jn01863
  16. Ni Y, Pislaru C, Bosmans H, Pislaru S, Miao Y, Bogaert J, Dymarkowski S, Yu J, Semmler W, Van de Werf F, Baert AL, Marchal G (2001) Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging. Eur Radiol 11:876–883
  17. Saeed M., Lund G., Wendland M. F., Bremerich J., Weinmann H.-J., Higgins C. B., Magnetic Resonance Characterization of the Peri-Infarction Zone of Reperfused Myocardial Infarction With Necrosis-Specific and Extracellular Nonspecific Contrast Media, 10.1161/01.cir.103.6.871
  18. Ni Y, Dymarkowski S, Chen F, Bogaert J, and Marchal G (2002) Occlusive myocardial infarction: enhanced or not enhanced with necrosis avid contrast agents at magnetic resonance imaging. Radiology 225:603–605
  19. Ni Y, Cresens E, Adriaens P, Dymarkowski S, Bogaert J, Zhang H, Bosmans H, Verbruggen A, Marchal G (2002) Exploring multifunctional features of necrosis avid contrast agents. Acad Radiol 9 [Suppl 2]:S488–S490
  20. Hermens A.F., Barendsen G.W., Cellular proliferation patterns in an experimental Rhabdomyosarcoma in the rat, 10.1016/0014-2964(67)90020-5
  21. Chen F, Sun X, De Keyzer F, Yu J, Peeters R, Coudyzer W, Vandecaveye V, Bosmans H, Van Hecke P, Landuyt W, Hermans R, Marchal G, Ni Y (2005) A rodent liver tumor model with implanted rhabdomyosarcoma: characterization using magnetic resonance, microangiography and histopathology. Radiology (in press)
  22. Cresens E, Ni Y, Adriaens P, Verbruggen A, Marchal G (2001) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them. International Patent Application PCT/BE01/00192 (7 November 2001)
  23. Marchal G, Verbruggen A, Ni Y, Adriaens P, Cresens E (1999) Non-porphyrin compounds for use as a diagnosticum and/or pharmaceutical. International Patent Application PTC /BE99/00104 (5 August 1999)
  24. Ni Y, Petré C, Miao Y, et al (1997) Magnetic resonance imaging—histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Invest Radiol 32:770–779
  25. Ni Y, Adzamli K, Miao Y, et al (2001) MRI contrast enhancement of necrosis by MP-2269 and Gadophrin-2 in a rat model of liver infarction. Invest Radiol 36:97–103
  26. Coad JE, Kosari K, Humar A, Sielaff TD (2003) Radiofrequency ablation causes thermal fixation of hepatocellular carcinoma: a post-liver transplant histopathologic study. Clin Transpl 17:377–384
  27. Miao Y, Ni Y, Mulier S, et al (2000) Treatment of VX2 liver tumor in rabbits with “wet” electrode mediated radio-frequency ablation. Eur Radiol 10:188–194
  28. Solbiati L, Livraghi T, Goldberg SN, et al (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 221:159–166
  29. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H (2005) Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol (in press), 2005 May 3 [Epub ahead of print]
  30. Langenhoff BS, Oyen WJ, Jager GJ, et al (2002) Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 20:4453–4458
  31. Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H (2003) FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 28:192–197
  32. Shreve Paul D., Anzai Yoshimi, Wahl Richard L., Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign Variants, 10.1148/radiographics.19.1.g99ja0761
  33. Cook GJ, Maisey MN, Fogelman I (1999) Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 26:1363–1378
  34. Ni Y, Marchal G (1998) Enhanced magnetic resonance imaging for tissue characterization of liver abnormalities with hepatobiliary contrast agents: an overview of preclinical animal experiments (review). Top Magn Reson Imaging 9:183–195
  35. Peng Q, Nesland JM (2004) Effects of photodynamic therapy on tumor stroma. Ultrastruct Pathol 28:333–340
  36. Van de Putte M, Roskams T, Vandenheede JR, Agostinis P, de Witte PA (2005) Elucidation of the tumoritropic principle of hypericin. Br J Cancer 92:1406–1413
  37. Ni Y, Chen F, Bormans G, Verbruggen A, Marchal G (2005) Targeting stroma: natural mechanisms derived from photodynamic therapy (PDT) and necrosis avid contrast agents (NACAs)? Mol Imaging 4:382 (abstract ID 556)
  38. Kim Tae Kyoung, Choi Byung Ihn, Park Sun Won, Lee Whal, Han Joon Koo, Han Man Chung, Weinmann Hans-Joachim, Gadolinium Mesoporphyrin as an MR Imaging Contrast Agent in the Evaluation of Tumors : An Experimental Model of VX2 Carcinoma in Rabbits, 10.2214/ajr.175.1.1750227
  39. Ju Lee H, Kim IO, Kim TK, Hyung Kim S, Choi JI, Woo Lee J, Kyung Moon W, Choi BI, Chung Han M, Weinmann HJ, Hyun Chang K (2002) Dynamic enhancement features of gadophrin-2 on magnetic resonance imaging: an experimental model of VX2 carcinoma and bacterial abscess in rabbit thigh. Invest Radiol 37:663–671